Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ROYALTY PHARMA PLC

(RPRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

11/29/2021 | 04:15pm EST

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com


Primary Logo

Source: RP Management, LLC

2021 GlobeNewswire, Inc., source Press Releases

All news about ROYALTY PHARMA PLC
01/20Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on Febru..
AQ
01/10Royalty pharma and cytokinetics announce funding agreements totaling up to $450 million
AQ
01/10MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guida..
AQ
01/10ROYALTY PHARMA : HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 40TH ANNUAL J...
PU
01/10Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J..
AQ
01/07Health Care Stocks Slumping Near Friday Close
MT
01/07Health Care Stocks Nearing Break-Even Mark Following Afternoon Uptick
MT
01/07Health Care Stocks Retreat Premarket Friday
MT
01/07Cytokinetics Secures Up to $450 Million in Funding From Royalty Pharma for Heart Diseas..
MT
01/07Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
GL
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Financials (USD)
Sales 2021 2 127 M - -
Net income 2021 937 M - -
Net Debt 2021 4 623 M - -
P/E ratio 2021 25,4x
Yield 2021 1,77%
Capitalization 16 807 M 16 807 M -
EV / Sales 2021 10,1x
EV / Sales 2022 9,45x
Nbr of Employees -
Free-Float -
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 39,13 $
Average target price 51,50 $
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer
George Lloyd Executive VP-Investments & General Counsel
Errol B. de Souza Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC-1.81%16 807
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093